scholarly journals Circulating miR-95 Is a Potential Biomarker of Chronic Lymphocytic Leukemia

2019 ◽  
Author(s):  
Behnaz Nateghi ◽  
Parisa Behshood ◽  
Sima Fathullahzadeh ◽  
Omid Mardanshah
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Real Time ◽  
Real Time Pcr ◽  
Mononuclear Cells ◽  
Lymphocytic Leukemia ◽  
Pathway Enrichment Analysis ◽  
Healthy Controls ◽  
Quantitative Real Time Pcr ◽  
Peripheral Blood Mononuclear ◽  
Potential Biomarker

Background: MicroRNAs (miRNAs) have crucial roles in cellular and molecular processes related to different malignancies including chronic lymphocytic leukemia (CLL). Studies revealed altered miR-95 expression in several diseases. Long non-coding RNAs (lncRNAs) are a heterogeneous group of non-coding and regulatory RNAs. Aim: The present study was conducted to investigate the association of miR-95 expression with CLL by quantitative real-time PCR. Materials and Methods: Sixty samples, including 30 CLL and 30 healthy controls, were sampled during a period of 4 months. The expression of miR-95 was evaluated by quantitative real-time PCR in peripheral blood mononuclear cells from patients with CLL and in healthy subjects. Additionally, in silico pathway enrichment analysis was performed on validated and predicted targets of miR-95 in several databases, including miRecords and miRTarBase, while the interactions between predicted putative lncRNAs and genes and miRNA expression were examined with miRWalk. Results: The expression of miR-95 was found to be significantly reduced in patients with CLL compared to that in healthy controls (P < 0.005). Conclusion: miR-95 showed potential as a biomarker for the early diagnosis of patients with CLL. LncRNAs play a significant role in regulating cellular evolution, differentiation, and other processes and may be important regulators in tumorigenesis.

Expression Profiles of miR-93 and miR-330 in Iranian Patients with Chronic Lymphocytic Leukemia

2019 ◽  
Author(s):  
Behnaz Nateghi ◽  
Elahe Shams ◽  
Parisa Behshood ◽  
Sima Fathullahzadeh ◽  
Mansoor Salehi
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Mononuclear Cells ◽  
Expression Profiles ◽  
Lymphocytic Leukemia ◽  
Human Leukemia ◽  
The Novel ◽  
Peripheral Blood Mononuclear ◽  
Potential Biomarker ◽  
Reverse Transcription Quantitative Pcr ◽  
Iranian Patients

Background and Aims: Chronic lymphocytic leukemia (CLL) is the most common adult human leukemia. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression. Research has shown that in CLL, microRNAs can have function as oncogenes or tumor suppressors. Some studies demonstrated that the expression of microRNA-93 (miR-93) and microRNA-330 (miR-330) have been changed in several cancers, including lung, prostate, and colon cancer. We aimed to elucidate the changes in miR-93 and miR-330 expression in CLL patients in comparison with controls. Materials and Methods: In this case-control study, the expression levels of miR-93 and miR-330 was evaluated in 30 CLL patients who had referred to Omid Hospital, Isfahan, Iran, and 30 controls in peripheral blood mononuclear cells using reverse transcription quantitative PCR (RT-qPCR). Results: The expression of miR-93 and miR-330 were found to significantly increase in CLL patients compared with controls (p<0.0001). Conclusions: The findings indicated that miR-93 and miR-330 are probably the novel potential biomarker for early diagnosis of CLL, at least in Iranian patients. However, for a decisive result, further investigations are warranted

scholarly journals Gammaretrovirus-Specific Antibodies in Free-Ranging and Captive Namibian Cheetahs

2015 ◽  
Vol 22 (6) ◽  
pp. 611-617 ◽  
Author(s):  
Annika Krengel ◽  
Valentino Cattori ◽  
Marina L. Meli ◽  
Bettina Wachter ◽  
Jürg Böni ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Real Time ◽  
Real Time Pcr ◽  
Mononuclear Cells ◽  
Leukemia Virus ◽  
Reverse Transcriptase Activity ◽  
Feline Leukemia Virus ◽  
Quantitative Real Time Pcr ◽  
Peripheral Blood Mononuclear ◽  
Free Ranging

ABSTRACTThe cheetah population in Namibia is the largest free-ranging population in the world and a key population for research regarding the health status of this species. We used serological methods and quantitative real-time PCR to test free-ranging and captive Namibian cheetahs for the presence of feline leukemia virus (FeLV), a gammaretrovirus that can be highly aggressive in populations with low genetic diversity, such as cheetahs. We also assessed the presence of antibodies to other gammaretroviruses and the responses to a FeLV vaccine developed for domestic cats. Up to 19% of the free-ranging cheetahs, 27% of the captive nonvaccinated cheetahs, and 86% of the captive vaccinated cheetahs tested positive for FeLV antibodies. FeLV-antibody-positive free-ranging cheetahs also tested positive for Rauscher murine leukemia virus antibodies. Nevertheless, FeLV was not detectable by quantitative real-time PCR and no reverse transcriptase activity was detectable by product-enhanced reverse transcriptase assay in the plasma of cheetahs or the supernatants from cultures of peripheral blood mononuclear cells. The presence of antibodies to gammaretroviruses in clinically healthy specimens may be caused either by infection with a low-pathogenic retrovirus or by the expression of endogenous retroviral sequences. The strong humoral immune responses to FeLV vaccination demonstrate that cheetahs can respond to the vaccine and that vaccination against FeLV infection may be beneficial should FeLV infection ever become a threat, as was seen in Iberian lynx and Florida panthers.

Validation of a quantitative real-time PCR assay for HTLV-1 proviral load in peripheral blood mononuclear cells

2013 ◽  
Vol 193 (2) ◽  
pp. 536-541 ◽  
Author(s):  
Carolina Rosadas ◽  
Mauro Jorge Cabral-Castro ◽  
Ana Carolina Paulo Vicente ◽  
José Mauro Peralta ◽  
Marzia Puccioni-Sohler
Keyword(s):  
Real Time ◽  
Peripheral Blood Mononuclear Cells ◽  
Real Time Pcr ◽  
Peripheral Blood ◽  
Proviral Load ◽  
Mononuclear Cells ◽  
Quantitative Real Time Pcr ◽  
Pcr Assay ◽  
Peripheral Blood Mononuclear ◽  
Blood Mononuclear Cells

Multidrug resistance in chronic lymphocytic leukemia

2008 ◽  
Vol 149 (4) ◽  
pp. 161-167 ◽  
Author(s):  
Tamás Szendrei ◽  
Tamás Magyarlaki ◽  
Gábor Kovács ◽  
Ágnes Nagy ◽  
Árpád Szomor ◽  
...  
Keyword(s):  
Multidrug Resistance ◽  
Chronic Lymphocytic Leukemia ◽  
Real Time ◽  
Real Time Pcr ◽  
Lymphocytic Leukemia ◽  
Light Cycler ◽  
Mdr 1

Az utóbbi években krónikus lymphoid leukaemiában új prognosztikai faktorok vizsgálata került a figyelem középpontjába. A citogenetikai eltérések, az immunglobulin-nehézlánc génmutációs státusza, a CD38- és ZAP70-expresszió mind a közelmúltban megismert prognosztikus faktorok, de kevés az adat a multidrog-rezisztencia jelentőségéről. Célok: A tanulmány célja genetikai, expressziós és funkcionális szinten jellemezni 82 krónikus lymphoid leukaemiában szenvedő beteg multidrog-rezisztenciájának sajátosságait, és vizsgálni azok összefüggését a betegek túlélésével és a kezelésre adott válasszal. Módszerek: a szerzők 66 betegnél vizsgálták az MDR-1 gén ben – Light Cycler Real Time PCR segítségével meghatározott – „Single Nucleotid Polymorphism” sajátosságot, amely irodalmi adatok szerint a P-glikoprotein expresszióját befolyásolja. Összesen 82 betegnél áramlási citometria során anti-P-glikoprotein monoklonális antitest segítségével a P-glikoprotein- expresszió t, az ún. calcein-verapamil teszttel pedig a multidrog-rezisztencia funkcióját vizsgálták. A kezelésre adott választ 35 betegnél vizsgálták, a statisztikai elemzésnél Fischer-tesztet alkalmazva. A túlélési analízist a teljes beteganyagon elvégezték ( n = 82, Log-rank-teszt). Eredmények: Az irodalmi adatokkal ellentétben a szerzők nem találtak korrelációt a vizsgált három multidrogrezisztencia-teszt között. A kezelésre adott választ vizsgálva 35 kezelt betegből 13 nonrespondernek, 22 pedig respondernek bizonyult. A P-glikoprotein-pozitív fenotípusú esetek ( n = 9) 89%-ban klinikailag nonrespondernek bizonyultak (9 P-glikoprotein-pozitív krónikus lymphoid leukaemiás beteg közül 8 nonresponder volt), a P-glikoprotein-negatív esetek ( n = 26) pedig 80%-ban jó terápiás választ mutattak (26 P-glikoprotein-negatív beteg közül 21 responder) ( p < 0,001). Az átlagos várható túlélésben is jelentős, bár nem szignifikáns ( p = 0,106) különbséget észleltek (84 vs 203 hónap). Következtetések: A vizsgált három laboratóriumi paraméter közül a P-glikoprotein sejtfelszíni jelenléte a leginkább releváns adat krónikus lymphoid leukaemiában a kemorezisztencia előjelzésére és a túléléssel kapcsolatban is prognosztikai faktorként értékelhető.

CircRNA profiling identifies circRNF180 as a tumor suppressor in hepatocellular carcinoma

Epigenomics ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 513-530
Author(s):  
Xi Zeng ◽  
Chao Tan ◽  
Meile Mo ◽  
Xiaoling Qin ◽  
Xiaoyun Ma ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Suppressor ◽  
Real Time ◽  
Real Time Pcr ◽  
Expression Profiles ◽  
Cell Counting ◽  
Migration And Invasion ◽  
Quantitative Real Time Pcr ◽  
Potential Biomarker ◽  
Hcc Cells

Aim: To explore the expression profiles and functions of circRNAs in hepatocellular carcinoma (HCC). Materials & methods: We obtained circRNA expression profiles through RNA sequencing. Expression levels of circRNAs were confirmed by quantitative real-time PCR. The effects on HCC progression were determined using Cell Counting Kit 8, clone formation and transwell assays. Results: We identified 114 upregulated and 144 downregulated circRNAs in HCC tissues. The results of quantitative real-time PCR showed that circGNAO1, circRNF180 and circMERTK were significantly downregulated in HCC tissues, whereas circSNX6 was significantly upregulated. CircRNF180 was associated with microvascular invasion. Overexpression of circRNF180 inhibits the proliferation, colony formation, migration and invasion of HCC cells. Conclusion: CircRNF180 may function as a tumor suppressor and could serve as a potential biomarker and therapeutic target in HCC.

scholarly journals Vadadustat, a HIF Prolyl Hydroxylase Inhibitor, Improves Immunomodulatory Properties of Human Mesenchymal Stromal Cells

Cells ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 2396
Author(s):  
Katarzyna Zielniok ◽  
Anna Burdzinska ◽  
Beata Kaleta ◽  
Radoslaw Zagozdzon ◽  
Leszek Paczek
Keyword(s):  
Real Time ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Real Time Pcr ◽  
Mononuclear Cells ◽  
Therapeutic Potential ◽  
Human Peripheral Blood ◽  
Immunomodulatory Activity ◽  
Peripheral Blood Mononuclear ◽  
Immunomodulatory Properties

The therapeutic potential of mesenchymal stromal cells (MSCs) is largely attributed to their immunomodulatory properties, which can be further improved by hypoxia priming. In this study, we investigated the immunomodulatory properties of MSCs preconditioned with hypoxia-mimetic Vadadustat (AKB-6548, Akebia). Gene expression analysis of immunomodulatory factors was performed by real-time polymerase chain reaction (real-time PCR) on RNA isolated from six human bone-marrow derived MSCs populations preconditioned for 6 h with 40 μM Vadadustat compared to control MSCs. The effect of Vadadustat preconditioning on MSCs secretome was determined using Proteome Profiler and Luminex, while their immunomodulatory activity was assessed by mixed lymphocyte reaction (MLR) and Culturex transwell migration assays. Real-time PCR revealed that Vadadustat downregulated genes related to immune system: IL24, IL1B, CXCL8, PDCD1LG1, PDCD1LG2, HIF1A, CCL2 and IL6, and upregulated IL17RD, CCL28 and LEP. Vadadustat caused a marked decrease in the secretion of IL6 (by 51%), HGF (by 47%), CCL7 (MCP3) (by 42%) and CXCL8 (by 40%). Vadadustat potentiated the inhibitory effect of MSCs on the proliferation of alloactivated human peripheral blood mononuclear cells (PBMCs), and reduced monocytes-enriched PBMCs chemotaxis towards the MSCs secretome. Preconditioning with Vadadustat may constitute a valuable approach to improve the therapeutic properties of MSCs.

Sign in / Sign up

Export Citation Format

Share Document